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Abstract: Medical advances continue to change the face of human immunodeficiency virus–
acquired immunodeficiency syndrome (HIV/AIDS). As life expectancy increases, the number 
of people living with HIV rises, presenting new challenges for the management of a chronic 
condition. Aging, nutrition, and physical activity can influence outcomes in other chronic con-
ditions, and emerging data show that each of these factors can impact viral replication and the 
immune system in HIV . HIV infection results in a decline of the immune system through the 
depletion of CD4+ T cells. From initial infection, viral replication is a continuous phenomenon. 
Immunosenescence, a hallmark of aging, results in an increased susceptibility to infections sec-
ondary to a delayed immune response, and this phenomenon may be increased in HIV-infected 
patients. Optimal nutrition is an important adjunct in the clinical care of patients with HIV . 
Nutritional interventions may improve the quality and span of life and symptom management, 
support the effectiveness of medications, and improve the patient’s resistance to infections and 
other disease complications by altering immunity. Moderate physical activity can improve many 
immune parameters, reduce the risk of acute infection, and combat metabolic abnormalities. As 
people with HIV age, alternative therapies such as nutrition and physical activity may comple-
ment medical management.
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Introduction
Human immunodeficiency virus (HIV) infection is no longer a disease of the young. It 
has been suggested that by 2015, 50% of those living with HIV in the United States will 
be 50 years of age and older.1 Similar trends have been appreciated in other developed 
nations.2,3 Reports for underdeveloped nations are limited, but recent data suggest the 
HIV-infected population over the age of 50 is increasing in some African countries.4,5 
Advances in antiretroviral (ARV) therapy have improved morbidity and increased 
longevity for both children and adults. Optimal medical management and enhanced 
laboratory monitoring for the effectiveness of treatment is also, in part, responsible 
for longer life expectancy. The face of HIV continues to evolve, and the disease is 
now considered a chronic condition. For people infected with HIV , more deaths are 
attributed to non-HIV related causes,6 including cardiovascular disease.
Acquisition of HIV can occur during the entire age spectrum from perinatal trans-
mission7 to disease acquired through risky behaviors in adolescence and adulthood.8 
Older individuals are generally not believed to be at as much risk for HIV; however, 
it has become evident that the incidence of HIV in this population is increasing.1–5 HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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The acute infection with HIV begins a cascade of nutritional 
and cardiometabolic events that are similar for many patients 
(Figure 1). Since the   cascade of events may occur across 
all age groups, many of the treatment goals are similar for 
all HIV-infected patients – to optimize immune function 
and to achieve the greatest degree of viral suppression 
while decreasing morbidity and mortality from secondary 
illness.9
From the initial infection, viral replication is a continu-
ous phenomenon. This process is evident even during the 
use of highly active ARV therapy (HAART).10 HIV disorders 
the immune system primarily through depletion of CD4+ 
T cells that are fundamental in the development of specific 
immune responses toward infectious agents. The immune 
system changes with age. “Normal” immune dysfunction 
is typically found at either end of the age spectrum – 
both infants and older people are at particular risk. This 
relative immunodeficient state is further compromised in 
  HIV-infected infants, young children, and older individuals. 
The older population, most commonly described as anyone 
with HIV over the age of 50, faces many challenges due 
to normal changes in the immune system. Aging is associ-
ated with immunosenescence that implies the increased 
susceptibility to infections secondary to a delayed immune 
response. In addition, older patients have a greater number 
of comorbidities that may further complicate their health. 
Thus, age, often, is an   independent factor that is associated 
with impaired immunologic responses.
ARVs have significantly improved morbidity and mor-
tality.11 Nutritional abnormalities, including both malnutri-
tion and obesity, are highly prevalent among HIV-infected 
children and adults and can independently contribute to 
declines in health and increases in mortality. Weight loss, 
cachexia, obesity, and cardiometabolic problems are a few 
of the nutritional factors that increase the risk of death.
Over the past decades, there have been multiple epide-
miological studies showing the relationship between physical 
activity and overall health in non-HIV populations. Physically 
active adults are less susceptible to viral and bacterial infec-
tions when compared with sedentary adults, suggesting that 
physical activity improves overall immune function. Research 
evidence supports the findings that exercise decreases age-
associated immunosenescence,12 increases innate immune 
function,13 and decreases chronic inflammation.14 Physical 
activity may be important to decrease the effects of some 
comorbidities such as lipodystrophy by increasing muscle 
mass, decreasing obesity by decreasing overall adipose tissue, 
and improving immune function by increasing T cells.
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Figure 1 Nutritional and cardiometabolic events with HIV infection. 
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This review will investigate how aging, nutrition, and 
exercise influence clinical and immunological outcomes in 
HIV infection.
Aging and HIV infection: 
immunological inferences
The process of aging produces a functional, biological, and 
psychological decline in an individual. These changes in 
total increase the overall risk of disease in older individuals. 
With aging, the body has a decreased ability to respond to 
stress, therefore, making a person prone to illness.15 The 
functional capabilities of the immune system decline with 
aging, and its decrease in capacity may lead to an increased 
susceptibility to infectious diseases and cancers.16 Dimi-
nution of immune function with age is associated with a 
decline in the production of growth hormone, estrogen, 
dehydroepiandrosterone, and melatonin.17 The changes in 
hormone levels are also associated with age-related degen-
erative diseases.18 It has been postulated that T and B cells 
play a critical role in the development of disorders more 
commonly seen with older age.19
The immune system encompasses innate, humoral, and 
cellular immunity. The newborn immune system is immature 
and leads to an increased susceptibility to both viral and 
bacterial pathogens.20 The humoral immune system is under-
developed in neonates with large dependence on maternally 
acquired antibodies.20 With age, there is a decrease in the 
functional ability of the natural killer (NK) cells21 despite a 
compensatory increase in the absolute number of NK cells.22 
Reports have also shown decreases in the number of mac-
rophages and granulocytes,23 cells that are important defense 
against microbes. Finally, proinflammatory cytokines such 
as interleukin-6 and intercellular adhesion molecule-1 are 
increased with aging and have been associated with morbid-
ity and mortality.24,25 Increased levels of immunoglobulins 
A and G with decreased numbers of B lymphocytes26 are 
most significant among the changes in humoral immunity 
with aging. The reduced responsiveness and altered antibody-
mediated defense mechanisms of the humoral immune 
system associated with senescence lead to an increased risk 
of disease. Cellular immunity is also affected with aging. 
Significant decreases are appreciated in CD3+, CD4+, and 
CD8+ cells and naïve T lymphocytes.27 These changes point 
to the decline in immunization response and are predictive 
of mortality.28
With advanced age, many diseases can mimic HIV , there-
fore, making the diagnosis at times delayed. The majority 
of older patients are diagnosed with HIV only when they 
become symptomatic, and the disease has progressed consid-
erably.29 There is evidence of accelerated immunosenescence 
in HIV-infected individuals as they age. The   replicative capa-
bilities of the cells of the immune system over a lifetime are 
limited, even under normal circumstances.30 Figure 2 shows 
the parallels between immunosenescence with normal aging 
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Figure 2 Schematic representation of immunosenescence with normal aging and that with HIV.
Copyright © 2002 elsevier. Reprinted with permission from Appay V, Rowland-Jones SL. Premature ageing of the immune system: the cause of AIDS? Trends Immunol. 
2002;23:580–585.31 
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and that with HIV .31 Chronic immune activation contributes to 
the early aging of the immune system in uninfected people. 
In HIV infection, HIV-specific CD8+ T cells express CD57, 
a senescence marker, soon after the patient is infected with 
HIV .32 Specific HIV-activated T-cell clones may prematurely 
reach replicative senescence with loss of CD8+ T-cell popula-
tions that typically control viral replication. Thus, the normal 
process of immunosenescence is likely accelerated in HIV .
The impaired renewal of T-cell populations can be caused 
by a number of factors in HIV infection. The thymus, which 
typically generates new populations of naïve T cells, under-
goes involution and atrophy in HIV-infected individuals.33 
Furthermore, there may also be a dysregulation of hematopoi-
esis where there are a lower absolute number of progenitor 
cells with decreased ability to generate new cells.34,35 Overall, 
the acceleration of immunosenescence in the HIV-infected 
individual may ultimately place the patient at higher risk of 
developing disorders associated with further impairment of 
the immune system (infections, cancers).
Clinically, during the pre-ARV therapy era, studies showed 
that HIV-infected patients of age 14–24 were anticipated to 
live 12.5 years on average, whereas those of age 45–54 were 
expected to live only 7.9 years on average.36 In addition, 
another study determined that the rate of CD4+ cell decline was 
significantly greater in the older group (over 40 years of age) 
when compared with the younger group (16–20 years of age).37 
There is an approximate inverse relationship between CD4+ 
cell count and survival time in most HIV cases.38 The increased 
rate of CD4+ decline in the older groups may in turn be associ-
ated with faster disease progression, and as CD4+ levels reach 
critical values, viral loads may increase.
The benefits of ARVs in reducing morbidity and mortality 
for patients with HIV–acquired immunodeficiency syndrome 
(AIDS) must be balanced against their potential side effects 
and toxicities. The ideal ARV is one that combines efficacy, 
adherence, tolerability, yet minimizes viral resistance.39 
The use of combination ARV therapy typically in the form 
of HAART can often achieve these goals.   Careful follow-
up care is important to prevent potential adverse events 
and   toxicity.40 More concerning is the fact that although 
  guidelines for HAART are described for children, adoles-
cents, and adults,41 there are no specific guidelines for the 
older patients with HIV despite the fact that this group is   
growing.
Older individuals with CD4+ levels below 500 cells/uL 
are associated with a death rate two times higher than those 
with a CD4+ of 650 cells/µL and above.42 The older popula-
tion may be at a disadvantage in maintaining higher CD4+ 
levels as they have diminished ability to stimulate CD4+ cells 
as a response to ARVs. A study by Goetz et al43 suggested 
that HIV-infected patients of 55 years and older demonstrated 
significantly lower CD4+ cell reconstitution when compared 
with the younger cohort. It has also been noted that persons 
with reduced immune system function, as found among older 
individuals, demonstrate a slower response to the effects of 
HAART.44 Therefore, older adults with long-term or new HIV 
infection can be challenging to manage clinically because of 
their altered responses to HIV and ARV therapy, owing to 
decreased immune function that comes naturally with aging 
but is likely exacerbated by HIV .
Nutrition, HIV, and immune 
response
Dietary therapy is an important adjunct in the clinical care 
of patients infected with HIV . In many conditions, achieving 
and maintaining optimal nutrition can improve an individual’s 
immune function, reduce the incidence of complications associ-
ated with HIV infection, attenuate the progression of HIV infec-
tion, improve quality of life, and ultimately reduce mortality 
associated with HIV .45 Multiple strategies to improve nutritional 
outcomes exist, including ARVs, treatment of coinfections, 
nutritional counseling, pharmacologic agents to stimulate 
appetite or anabolism, and nutritional supplements. This section 
discusses the effects of nutrition therapy on immunologic status 
and how nutrition may alter the natural course of HIV .
Nutritional complications remain a challenging issue for 
HIV-infected children and adults in the HAART era and can 
often contribute to both morbidity and mortality of those 
infected with HIV . Weight loss, lean tissue depletion, lipoa-
trophy, anorexia, nutrient malabsorption, diarrhea-induced 
nutrient losses, and a hypermetabolic state increase risk of 
death.46 In addition, several non-AIDS-related problems such 
as serum lipid abnormalities, insulin resistance, osteopenia, 
and increased risk for cardiovascular diseases have emerged 
since the introduction of HAART.
Several HIV-specific medications, particularly nucleo-
side reverse transcriptase inhibitors, may inhibit replication 
of mitochondrial DNA and cause vomiting and diarrhea 
that may result in the loss of micronutrients. Mitochondrial 
toxicity may also increase the production of reactive oxygen 
species, which cause oxidative damage, leading to lactic 
acidosis. Mitochondrial dysfunction may be responsible for 
HAART-associated lipodystrophy.47 Protease inhibitor ther-
apy has been linked to lipid abnormalities48 and changes in 
cardiovascular risk profiles49,50 with decreased brachial artery 
reactivity51 and greater carotid intima media   thickness.52 HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Although non-nucleotide reverse transcriptase inhibitors 
are not associated with as many adverse cardiovascular 
risks, they have their own set of toxicities in other systems.53 
Patients beginning combination therapy, or HAART, often 
experience a gain in central adiposity and lean mass over the 
first 6 months and may develop glucose intolerance, insulin 
resistance, hyperlipidemia, and peripheral lipoatrophy and 
decrease in lean mass after 6 months.54
Patients who have nutritional and metabolic distur-
bances that result in weight loss and wasting may show a 
chronic inflammatory state. Inflammation and other immune 
responses alter nutritional status through sequestration of 
minerals (eg, iron and zinc), impaired absorption, increased 
nutrient loss, or altered nutrient utilization.55
Micronutrients are essential for maintaining proper 
immunologic function. Cellular mechanisms by which trace 
elements and other nutrients can influence immunity include 
nutrient effects on protein synthesis, cytokine production, 
mitosis, apoptosis, and signal transduction.56 Micronutrient 
deficiencies, as a result of acute or chronic inflammation, 
can persist in the HAART era. Studies suggest low serum 
levels of retinol, α-tocopherol, selenium, and zinc acceler-
ate the progression of HIV to AIDS and death.57,58 In certain 
clinical situations of stress, the production of free radicals is 
greater than their normal clearance. At that point, the host’s 
endogenous antioxidant system plays a major role to prevent 
or limit the deleterious effects of free radicals and, in patients 
with HIV , maintain immune function.58–60 Endogenous 
antioxidants include enzymatic antioxidants (eg, zinc in 
superoxide dismutase or selenium in glutathione peroxidase), 
free radical scavengers (eg, vitamins A, C, or E), and metal 
chelators.61 Sources of antioxidants include the diet or the 
use of specific nutritional supplements. Increased free radical 
formation and reduced antioxidant defenses can result from 
a combination of insufficient dietary intake and excessive 
utilization of specific antioxidants without adequate recycling 
or replacement. Recognizing and correcting multiple vitamin 
marginal deficiencies may be the key to the treatment of many 
HIV-infected patients.
Nutritional status influences the immune system at dif-
ferent levels. Subclinical or frank deficiencies of micronu-
trients reduce circulating amounts and functional capacities 
of key immune cells and proteins, including innate immu-
nity and components of adaptive immunity such as T- and 
B-  lymphocyte functions. Other micronutrient deficiencies, 
including that of essential fatty acids, folate, zinc, and vitamin 
A, may lead to mucosal lesions or reduced mucosal integrity, 
thus increasing the risk of infections.62
Essential trace elements (Cu, Fe, Se, and Zn) can 
  influence immunity due to their presence in metalloenzymes 
that have key immunologic functions. For instance, zinc is 
essential for the development of immunity during childhood 
because of its global role in the normal development and 
function of cell-mediating innate immunity, neutrophils, NK 
cells, and macrophages. Among vitamins, vitamin A defi-
ciency reduces lymphocyte response, vitamin C deficiency 
depresses cell-mediated immune response, and vitamin E 
deficiency impairs T cell-mediated function and lympho-
cyte proliferation. Deficiency of any single nutrient may 
impair resistance to infection, and conversely, infections, 
even if mild, may result in adverse effect on nutritional   
status.63
The keystones of mounting an effective immune 
response are rapid cellular proliferation and early synthesis 
of regulatory and/or protective proteins. Deficiencies of 
essential nutrients are potentially one of the rate-limiting 
factors in the development and maintenance of immune 
responses. A summary of the effects of nutrition interven-
tions on the immune function of HIV-infected patients is 
described in Table 1.
Macronutrients interventions
Adequate intake of micronutrients and macronutrients is 
essential for the restoration and maintenance of body cell 
mass and normal function, including immunity. The benefits 
of providing adequate amounts of energy and protein for 
people living with HIV are clear.73
The evidence of the effects of macronutrient interventions 
in reducing viral load and morbidity and mortality in children 
and adults living with HIV is sparse. Studies using supple-
mental formulas, such as those with hydrolyzed or elemental 
protein and special protein formulas with whey, glutamine, 
arginine, or high protein content;70 lipids including fish oil 
or n-3 fatty acids;74 and fiber interventions,75 suggest that 
macronutrient supplementation may increase energy intake 
but do not reliably result in increases in fat-free mass, body 
cell mass, or immunological parameters such as CD4+ count. 
A cross-sectional study of men with advanced, asymptomatic 
HIV demonstrated a positive association between protein 
intake and body cell mass independent of muscle-building 
activity.76 Clark et al70 demonstrated that supplementation 
with specific nutritional supplements, including an amino 
acid mixture of arginine, glutamine, and β-hydroxy- 
β-methylbutyrate, significantly increased body weight and 
decreased viral load but did not alter energy intake, protein 
intake, fat mass, or CD4+ count. Although studies have HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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shown the potential benefits of n-3 fatty acids on immune 
function for people with HIV , the recommended intake is 
currently the same as for the general population.77,78
Micronutrients interventions
Micronutrient supplements may provide cellular and 
clinical benefits for HIV-infected patients on HAART. 
  Growing evidence supports the importance of essential trace 
  elements – particularly copper, iron, selenium, and zinc – for 
maintaining immune functions.68,69,79 However, micronutri-
ent supplementation has shown mixed beneficial effects on 
immunologic status.80,81
A comprehensive review of randomized trials showed 
that there was no conclusive evidence that micronutrient 
supplementation (including vitamins A, C, and E, selenium, 
zinc) effectively reduced morbidity and mortality among 
HIV-infected children, adults, and pregnant and lactating 
women.82
Other studies provide additional support for micronutrient 
supplementation in HIV . Vitamin D deficiency is prevalent 
in HIV-infected individuals83 and is an emerging nutrient 
that can positively affect immune function, among other 
important roles. In one study of over 800 women in Tanzania, 
women with the highest levels of vitamin D had decreased 
all-cause mortality, HIV disease progression, and anemia.84 
These effects may, in part, be due to the role of vitamin D 
in immune regulation. Vitamin D receptors have been found 
on peripheral blood mononuclear cells, and this suggests 
vitamin D can be an immune modulator.64 Vitamin D has 
also been shown to have an integral role in innate immunity 
and response to infections such as tuberculosis.65
Other investigators have demonstrated that antioxidant 
supplementation improved some measures of oxidative 
defense in HIV+ adults on HAART.66,67 In another review 
of randomized clinical trials, Allen et al81 concluded that 
there is some evidence that supplementation with multiple 
micronutrients reduces mortality and possibly morbidity, 
among adults with HIV/AIDS not on HAART. Additional 
studies are still needed to investigate the effects of multiple 
micronutrients as an adjunct therapy for people receiving 
HAART.
Micronutrient supplements may not always prove to be 
beneficial in HIV-infected individuals. Supplementation 
with trace elements as single nutrients may lead to micro-
nutrient imbalances, especially in populations with multiple 
  underlying deficiencies.85 Both iron deficiency and excess 
Table 1 Summary of the effects of nutrition interventions on the immune function of HIV-infected patients
Nutrition intervention Effects on immune function
Antioxidant supplementation – vitamins A, C, and e  
and selenium
May decrease oxidative stress and increase oxidative defenses66 
May increase CD4+ cell count67 
Increases concentrations of serum vitamins A, C, and e68
Selenium supplementation Increases serum selenium concentrations69 
May reduce the risk of a decrease in CD4+ cell count69 
May decrease frequency of hospitalizations69
Multiple micronutrient supplementation May reduce morbidity and mortality81
Vitamin D May potentiate innate immune response to infection65 
May decrease HIV disease progression64
Nutritional supplements including an amino acid mixture  
of arginine, glutamine, and leucine metabolites,  
β-hydroxy-β-methylbutyrate
May promote increase in CD3 and CD8 lymphocyte counts and  
decrease in the HIV viral load70 
Promote weight gain, predominantly lean body mass, in HIV+ 
patients with muscle wasting70
Fish oil or n-3 fatty acids (ePA and DPA) Variations in the ratio of (n-6):(n-3) may modulate  
inflammation, clotting, and vascular responses71 
Reduces cytokine activity and promotes weight gain in patients  
without AIDS-related complications72
Optimal nutrition May help improve the quality and length of life73 
Improves symptom management, supports the effectiveness of  
medications and other therapies73 
Improves patients’ resistance to infections and other disease  
complications73
Combination of ARV drug therapy, appropriate and  
adequate dietary intake, frequent exercise, and a  
low-dose multivitamin or mineral supplement
May be effective, especially in the treatment of HIV-infected  
patients
Abbreviations: ePA, eicosapentaenoic acid; DPA, docosapentaenoic acid; ARV, antiretroviral.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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iron may inhibit some immune functions.79 Likewise with 
zinc, both deficiency and excessive intake are correlated 
with reduced CD4 cell counts and survival of the patient 
with HIV .86 High doses of zinc supplementation may lead to 
zinc-induced copper deficiency87 that may further compro-
mise the immune system. Micronutrient supplementation has 
also been associated with HIV transmission.   Randomized 
trials have shown that maternal vitamin A supplements 
increase the risk of mother-to-child transmission of HIV88 
and can increase mortality in some children born to HIV+ 
mothers.89
There is growing evidence that routine ingestion of a 
multivitamin or mineral supplement that includes moderate 
quantities of essential trace elements may result in improve-
ments in immune functions in older people.85 However, legiti-
mate use of dietary supplementation is to restore a deficiency. 
Currently, no conclusive evidence supports the use of dietary 
supplement solely on the basis of improving infectious 
outcomes in well-nourished HIV-infected individuals. The 
World Health Organization promotes and supports adequate 
dietary intake of micronutrients at Dietary Reference Intakes 
(DRIs) levels.90 It suggests that patients are likely to benefit 
from consuming a varied diet that is rich in micronutrients. 
It is likely that HIV-infected patients, particularly those with 
poor diets or who live in poverty, may benefit from regular 
consumption of a multivitamin, mineral, and trace element 
supplement that contains micronutrients at DRI levels.
Good nutrition and nutrition interventions may help 
improve the quality and length of life, improve symptom man-
agement, support the effectiveness of medications and other 
therapies, and improve the HIV-infected patient’s resistance 
to infections and other disease complications.73
Physical activity and immune 
function
Over the past few decades, epidemiological studies have 
demonstrated the relationship between physical activity and 
overall health.91 The Centers for Disease Control and Preven-
tion reports that all ages can benefit from moderate amounts 
of daily activity.87 Physical activity has been shown to assist 
in weight management, lean muscle development, and body 
fat reduction.92 However, in individuals with chronic illness, 
it is important to determine the effectiveness and safety of 
physical activity to ensure the benefits outweigh the risks.
Physically active adults are less susceptible to viral and 
bacterial infections when compared with sedentary adults, 
suggesting that physical activity improves overall immune 
function. Scientific evidence suggests that exercise delays 
age-associated immunosenescence,12 increases innate 
immune function,13 and decreases chronic inflammation.14 
Improved immune function plays a critical role in regulating 
the inflammatory process, a primary contributor to chronic 
disease.93 Because T-lymphocyte function declines with 
age, preserving this function with interventions known to 
improve immunity, such as physical activity, is considered 
important.13 For example, one study in an older population 
reported that 6 months of aerobic and resistance training at 
moderate intensity showed significantly increased CD28+ and 
CD4+ cells, causing an upregulation of the T-helper cells and 
decreasing the risk of infection.94
In addition, physical activity can effectively reduce 
both acute and chronic inflammation.12 A reduction in the 
chronic inflammatory process, as shown in Figure 1, may 
inhibit metabolic disturbances and the risk for concomitant 
diseases. Physical activity can also stimulate the production 
of   hormones. Starkie et al95 demonstrated that the levels of 
the stress hormones such as glucocorticoids and epinephrine 
increase with bouts of exercise. The release of these hormones 
leads to an acute decrease of inflammation. Thus, in addition 
to the beneficial effect of lowering levels of inflammatory 
markers, there is evidence that physical activity stimulates 
production of anti-inflammatory factors as well.96
HIV infection dramatically changes the physical well-
being of an individual, yet the current treatments make it 
possible for this population to live longer and with greater 
quality years of life. With this increase in longevity, other 
chronic conditions are emerging that relate to both normal 
aging and complications of medical treatments and chronic 
viral infection. As previously reviewed, individuals with HIV 
are becoming more susceptible to conditions such as insulin 
resistance, dyslipidemia, and cardiovascular disease.97 Up to 
60% of HIV-infected patients receiving HAART have body 
composition and metabolic abnormalities.98 HIV-infected 
patients, including children,99,100 have demonstrated positive 
health and fitness parameters when participating in struc-
tured physical activity interventions, including improved 
overall quality of life. The effects of physical activity on 
HIV-infected individuals include physical improvements 
in body composition with decreased waist circumference 
and waist-to-hip ratio and increased lean body mass, and 
cardiometabolic fitness – all risk factors for cardiovascular 
disease.99–102
Similar to the general population, HIV-infected patients 
are at risk for obesity.103 Amorosa et al104 report a higher preva-
lence in overweight and obesity compared with   wasting that 
was most prevalent in the pre-HAART era. The   prevalence of HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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metabolic syndrome among HIV patients is reported between 
14% and 18% depending on the definition of the diagnosis.105 
As a result, healthcare professionals suggest exercise as a 
management strategy to improve lean body mass and car-
diovascular fitness and decrease metabolic complications of 
HIV . Obesity alone can negatively impact immune function. 
A recent report demonstrated that obese patients had lower 
levels of CD4 cell counts106 and may be associated with slower 
immunological recovery. Others have shown that obese indi-
viduals have higher inflammatory biomarkers and adipokines 
that may negatively impact the overall function of the immune 
system.107–109 Taken collectively, obese HIV-infected individual 
may be at a higher risk of immune dysfunction compared with 
normally nourished patients. Interventions, such as physical 
activity, that can impact obesity may be beneficial in improv-
ing immune function.
Regular physical activity can positively affect the HIV-
infected individual psychologically, and emotional wellness 
has been linked directly related to immune health. Studies 
have reported a 22%–45% prevalence of depression among 
HIV-infected people.110 This high prevalence indicates that 
depression is a disease that needs to be assessed in all patients 
with HIV . Depression has been linked to altering the course of 
infection due to immune function impairment. HIV-infected 
patients who participate in regular physical activity have 
higher life satisfaction scores when compared with those 
who are sedentary.111
The immunological benefits of physical activity, specific 
to those with HIV infection, include the effects on CD4+ 
T-lymphocyte counts and HIV viral load. Participants in one 
study, who participated in aerobic physical activity, showed 
enhanced production of natural antibodies that, in turn, can 
potentially delay disease progression. These results suggest 
that physical activity can positively affect immunological 
factors that usually cause disease progression in HIV .112 
Broadbent and Gass113 found that 52 weeks of physical 
activity increases CD4+ and CD25+ percentages in older 
men. Another study reported an inverse relationship between 
regular physical activity and viral load,114 a finding that had 
not been previously supported in the literature. However, most 
reports indicate that exercise does not positively or negatively 
impact CD4 count or viral load.99,102,115 The inconsistency 
of these results emphasize the need for additional studies 
that control for the amount and intensity of the physical 
activity intervention, as well as the stage and progression 
of the disease. Overall, existing literature indicates exercise 
interventions are physically and immunologically safe in both 
children and adults with HIV .
As the evidence for the benefits of physical activity on 
immune and metabolic functions in persons with HIV grows, 
recommendations for regular exercise should become an 
integral part of their care across all ages.
Conclusion
HIV-infected children and adults are now expected to live 
longer, but at the same time, they are at risk for developing 
health complications as a consequence of a life with chronic 
viral infection, exposures to medications that carry their 
own toxicities and side effects, and the natural effects of 
aging on the immune system. Age-related immunosenes-
cence can increase the challenges of controlling viral loads 
and optimizing CD4+ T-lymphocyte cell counts. Because 
immunosenescence is an inherent phenomenon that may be 
accelerated by HIV , strategies that can potentially modify this 
process should be used. Nutrition therapy may support the 
effectiveness of the medical treatments by improving cellular 
function through the supplementation of both macronutrients 
and micronutrients. Physical activity, known to provide a 
number of benefits for noninfected individuals, can exert 
positive effects on metabolic and cardiovascular functions 
while not imposing deleterious effects on the immune 
system. Continued research is needed to further define the 
effects of optimal nutrition and physical activity on the 
immune system as HIV-infected individuals grow older.
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